Abstract
RNA interference (RNAi) is a collection of small RNA-directed mechanisms that result in sequence-specific inhibition of gene expression. RNAi delivery has demonstrated promising efficacy in the treatment of genetic disorders in cancer. Although viral vectors are currently the most efficient systems for gene therapy, potent immunogenicity, mutagenesis, and the biohazards of viral vectors remain their major risks. Various non-viral delivery vectors have been developed to provide a safer approach for gene delivery, including polymers, peptides, liposomes, and nanoparticles. However, some concerns and challenges of these non-viral gene delivery approaches remain to be overcome. In this review, we summarize the recent progress in the development of non-viral systems delivering RNAi and the currently available preclinical and clinical data, and discuss the challenges and future directions in cancer therapy.
Keywords: Cancer gene therapy, liposomes, microRNA, non-viral delivery, nuclear localization signal, polymers, RNA interference, siRNA.
Current Gene Therapy
Title:Non-Viral Delivery of RNA Interference Targeting Cancer Cells in Cancer Gene Therapy
Volume: 12 Issue: 4
Author(s): Pin-I Huang, Wen-Liang Lo, Jong-Yuh Cherng, Yueh Chien, Guang-Yuh Chiou and Shih-Hwa Chiou
Affiliation:
Keywords: Cancer gene therapy, liposomes, microRNA, non-viral delivery, nuclear localization signal, polymers, RNA interference, siRNA.
Abstract: RNA interference (RNAi) is a collection of small RNA-directed mechanisms that result in sequence-specific inhibition of gene expression. RNAi delivery has demonstrated promising efficacy in the treatment of genetic disorders in cancer. Although viral vectors are currently the most efficient systems for gene therapy, potent immunogenicity, mutagenesis, and the biohazards of viral vectors remain their major risks. Various non-viral delivery vectors have been developed to provide a safer approach for gene delivery, including polymers, peptides, liposomes, and nanoparticles. However, some concerns and challenges of these non-viral gene delivery approaches remain to be overcome. In this review, we summarize the recent progress in the development of non-viral systems delivering RNAi and the currently available preclinical and clinical data, and discuss the challenges and future directions in cancer therapy.
Export Options
About this article
Cite this article as:
Huang Pin-I, Lo Wen-Liang, Cherng Jong-Yuh, Chien Yueh, Chiou Guang-Yuh and Chiou Shih-Hwa, Non-Viral Delivery of RNA Interference Targeting Cancer Cells in Cancer Gene Therapy, Current Gene Therapy 2012; 12 (4) . https://dx.doi.org/10.2174/156652312802083576
DOI https://dx.doi.org/10.2174/156652312802083576 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Production of β -cyclodextrin from pH and Thermo Stable Cyclodextrin Glycosyl Transferase, Obtained from Arthrobacter mysorens and Its Evaluation as a Drug Carrier for Irbesartan
Current Drug Delivery Overcoming the Drug Resistance Problem with Second-Generation Tyrosine Kinase Inhibitors: From Enzymology to Structural Models
Current Medicinal Chemistry Cytotoxic, Antiproliferative and Apoptotic Effects of New Benzimidazole Derivatives on A549 Lung Carcinoma and C6 Glioma Cell Lines
Anti-Cancer Agents in Medicinal Chemistry HSP60 as a Drug Target
Current Pharmaceutical Design 2´,3´-Dialdehyde of ATP, ADP, and Adenosine Inhibit HIV-1 Reverse Transcriptase and HIV-1 Replication
Current HIV Research The Role of Connexins in Carcinogenesis: Review of Current Knowledge
Current Signal Transduction Therapy Gene Therapy for Parkinsons and Alzheimers Diseases: from the Bench to Clinical Trials
Current Pharmaceutical Design Spontaneous Chest Abscess Caused by Salmonella Enterica subsp. Arizonae in the Desert Southwest; A Case Report and Review of the Current Literature
Infectious Disorders - Drug Targets Aldehyde Dehydrogenase as a Marker for Stem Cells
Current Stem Cell Research & Therapy Dendritic Cells in Esophageal Adenocarcinoma: The Currently Available Information and Possibilities to use Dendritic Cells for Immunotherapeutic Approaches
Current Pharmaceutical Design Incorporating Link Information in Feature Selection for Identifying Tumor Biomarkers by Using miRNA-mRNA Paired Expression Data
Current Proteomics BRCA-FA Pathway as a Target for Anti-Tumor Drugs
Anti-Cancer Agents in Medicinal Chemistry Preparation and Quality Control of <sup>111</sup>In-Plerixafor for Chemokine Receptor CXCR4
Recent Patents and Topics on Imaging (Discontinued) Oncogenic LncRNA CASC9 in Cancer Progression
Current Pharmaceutical Design Salinomycin: A Novel Anti-Cancer Agent with Known Anti-Coccidial Activities
Current Medicinal Chemistry Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases
Current Genomics Diagnostic and Therapeutic Applications of Recombinant Antibodies:Targeting the Extra-Domain B of Fibronectin, A Marker of Tumor Angiogenesis
Current Pharmaceutical Design Annexins as Neuroprotective Agents in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Recent Developments in Anti-Cancer Agents Targeting the Ras/Raf/ MEK/ERK Pathway
Recent Patents on Anti-Cancer Drug Discovery Review of the Contribution of Radiolabelled Tracers for Tumour Cell Status Imaging
Current Medical Imaging